Most Recent Articles by Corinna Panlilio Sison, MD
Beta-blocker use was associated with less joint pain and lower use of opioids in patients with symptomatic, large joint radiographic OA.
In this meta-analysis, the researchers found that all TNF-α inhibitors were more effective at treating AS than placebo in direct comparisons, but no differences in efficacy or safety were found between individual TNF-α inhibitors in indirect comparisons.
Selective inhibition of JAK1 and JAK2 with baricitinib resulted in clinical improvements in RA symptoms and inhibited joint structural disease progression in patients with active RA who have failed csDMARDs.
The European League Against Rheumatism has released updated management guidelines to address cardiovascular disease risk assessment in patients with rheumatoid arthritis and other inflammatory arthritides.
More Articles by Corinna Panlilio Sison, MD
Rheumatology Advisor Articles
- Rheumatoid Arthritis Increases Mortality Risk in Staphylococcus aureus Infections
- First Clinical Practice Guidelines for Sjögren's Syndrome Developed
- Antibiotic Resistance Problem Brought Before Congress
- FDA Delays Approval of JAK Inhibitor Baricitinib
- How Effective is RF Denervation for Symptomatic Knee OA?
- Allopurinol Use In Concomitant Gout and Diabetes Lowers Cardiovascular Event Risk
- Measuring Disease Activity in Psoriatic Arthritis
- JAK/STAT Inhibitors: A New Treatment Target for Rheumatoid Arthritis
- Biosimilar Confidence: Physician-Patient Communication Sets the Tone
- VA and DoD Practice Guideline Update: Opioids for Chronic Pain
- Leg Positioning During Lumbar DXA Does Not Impact Trabecular Bone Scores
- Should Trabecular Bone Score Be Used to Predict Fragility Fracture Risk in T1D?
- DXA for Pediatric Bone Age Assessment Yields Similar Results vs Traditional Radiography
- Remote Osteoporosis Specialist Mentoring Program Improves Physician Self-Confidence
- Increased Costs Associated With Specialists Providing Primary Care